12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Company News  |  Other News

Ablynx antibodies news

Ablynx said it plans to separate the chairman and CEO roles at its next shareholder meeting on Nov. 7. The nanobody company said it will name Peter Fellner chairman, while Edwin Moses, currently chairman and CEO, will remain CEO. Ablynx said Belgian law requires having a separate...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >